Obesity and Lifestyle Changes for Cardiometabolic Care

Learn about the significance of cardiometabolic care for obesity in promoting healthier lifestyles and preventing diseases.

Abstract

In this educational post, I, Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, present a comprehensive, first-person exploration of integrated obesity and metabolic care through real-world cases and evidence-based practice. This post will guide you through the clinical journeys of “Eloise,” “George,” “Amin,” and “Dolores”—patients grappling with a constellation of issues including women’s and men’s obesity, polycystic ovary syndrome (PCOS), insulin resistance, male infertility, sarcopenia (muscle loss), and joint preservation for osteoarthritis. This narrative showcases how we, at Injury Medical Clinic PA, utilize a comprehensive, integrative framework to address the deep physiological underpinnings of these conditions. We will delve into the intricate hormonal feedback loops involving testosterone, estrogen, cortisol, insulin, ghrelin, and leptin, explaining how excess adipose tissue drives a cascade of metabolic and psychological distress.

With medical direction from Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), our multidisciplinary team at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic, El Paso, Texas) merges chiropractic care, internal medicine, functional medicine, rehabilitation, and personal injury management. We review the latest findings from leading researchers, explain the physiology of obesity, insulin resistance, and related disorders, and demonstrate how precision nutrition, activity progression, pharmacotherapy—such as metformin, semaglutide, tirzepatide, bupropion/naltrexone, and phentermine/topiramate—plus chiropractic and rehabilitation strategies can reduce cardiometabolic risk, improve function, and enhance quality of life.

This is a long-form, in-depth resource designed to be easy to follow, compassionate, and clinically actionable. It illustrates our step-by-step integration of care, the rationale behind every choice, and the practical methods we use to address medical bias, patient fears, and system-level barriers. Readers will learn why small activity increments matter, how to protect muscle mass during weight loss, what HOMA-IR and visceral adipose tissue indicate, and how to safely combine or sequence anti-obesity medications with surgery and rehabilitation plans.

Our Integrative Clinic: A Collaborative Model for Comprehensive Care

Before we delve into our case studies, I believeit’ss essential to provide some context about our unique clinical environment at Injury Medical Clinic PA here in El Paso, Texas. My name is Dr. Alex Jimenez, and my professional journey has led me to hold several qualifications, including Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN) with a Family Nurse Practitioner board certification (FNP-BC), and certifications in Functional Medicine (CFMP, IFMCP), among others. This diverse background allows me to view patient health through multiple lenses—structural, neurological, metabolic, and systemic.

However, true integrative care is not a solo endeavor. It thrives on collaboration. I am privileged to work alongside Dr. Maria Guadalupe Cardenas, MD, a highly respected and experienced board-certified internist who serves as our practice’s Medical Director and Collaborative Physician. With over 40 years in internal medicine, Dr. Cardenas brings an incredible depth of medical knowledge and diagnostic acumen to our team. Her NPI is #1164426749, and she is licensed in Texas under #J2933.

This multidisciplinary structure is the cornerstone of our practice. It allows us to seamlessly blend chiropractic care, medical management, functional medicine, personal injury rehabilitation, and nutritional science. When a patient presents with complex issues spanning multiple body systems, Dr. Cardenas and I collaborate closely. While I may focus on the musculoskeletal aspects, neurological function, and functional medicine protocols, Dr. Cardenas provides essential medical oversight, manages prescriptions, and ensures that our treatment plan is safe, effective, and adheres to the highest standards of medical care. This partnership ensures that patients receive a truly holistic and robust treatment plan that addresses their health from every possible angle. It’s a model designed to break down the silos of traditional healthcare and build a comprehensive, patient-centered journey to wellness.

My clinical observations and thought leadership are continuously shared through WellnessDoctorRx and professional updates on LinkedIn, supporting transparent, evidence-guided care.

• WellnessDoctorRx: https://wellnessdoctorrx.com/
• LinkedIn (Dr. Alex Jimenez): https://www.linkedin.com/in/dralexjimenez/

At a glance: How we integrate care for obesity and metabolic disorders

• Medical direction and safety: Internal medicine oversight from Dr. Cardenas supports medication selection, lab monitoring, risk mitigation, and coordination with specialists.
• Chiropractic integration: I use chiropractic to optimize spinal and joint mechanics, reduce pain, and restore movement competency. This improves autonomic balance, reduces systemic stress signaling, enhances physical activity capacity, and supports metabolic resilience.
• Functional medicine analytics: We assess gut health, inflammation, endocrine function, micronutrient status, sleep and stress biomarkers, and environmental factors. We correct root causes that impair insulin signaling and appetite regulation.
• Rehabilitation and movement: We prescribe graded aerobic sessions, strength training, and mobility sequences tailored to insulin sensitivity, energetic capacity, and pain status.
• Behavioral and nutrition strategies: We focus on reduced-carbohydrate patterns for insulin resistance, targeted protein, fiber, meal timing for satiety, and psychological safety to reduce binge patterns.
• Pharmacologic therapy: Under Dr. Cardenas’s oversight, we titrate agents like metformin, GLP-1/GIP therapies, and other anti-obesity medications when appropriate, and manage contraceptive considerations in PCOS and fertility planning.
• Personal injury and comorbidity integration: For patients with injuries, we manage pain and movement before intensifying exercise. This avoids relapse into sedentary behaviors that worsen insulin resistance.

Introduction: Reframing Obesity Care Through an Integrative Lens

Obesity is not merely a matter of calories consumed and calories expended. It is a chronic, relapsing, multifactorial condition rooted in dysregulated energy homeostasis, hormonal signaling, neurobehavioral pathways, chronic inflammation, and often pain-driven inactivity. I have seen in practice that addressing obesity demands:

• Precision identification of metabolic impairments in insulin, leptin, and adipokine signaling.
• Correction of autonomic imbalances and pain syndromes that suppress activity and increase stress hormones.
• Strategic nutrition patterns that honor satiety biology, preserve lean mass, and stabilize blood glucose.
• Psychological safety and behavioral tools to reduce shame cycles and binge episodes.
• Pharmacologic support when physiological resistance blocks progress.
• Interdisciplinary execution to keep care safe, coherent, and sustainable.

With medical oversight from Dr. Maria Cardenas, we maintain high standards of safety and effectiveness. My role as a chiropractor and functional medicine provider is to integrate movement science, neuro-musculoskeletal care, and lifestyle therapeutics to translate metabolic improvements into everyday function and quality of life. This post guides you through case-based narratives—adapted into a first-person perspective—that illustrate how we synthesize the latest evidence with clinical wisdom to help patients move from metabolic rigidity to sustainable metabolic flexibility.

Women’s Case Study: Eloise and the Journey to Metabolic Flexibility, Fertility, and Resilience

Eloise’s Story at a Glance

• Age: 25
• Occupation: Director of fitness at the Y
• Primary concerns: Weight cycling, irregular, infrequent menses since adolescence, cystic acne, upper lip hair, anxiety around calories with intermittent binge eating, infertility (sexually active 5 years, no contraception, no pregnancies)
• Key labs and exam: BMI 37.5, fasting insulin 36.1, fasting glucose 107 mg/dL, A1C 6.0, HOMA-IR 9.5, dyslipidemia (elevated triglycerides, low HDL, elevated LDL), elevated liver enzymes, waist circumference elevated, acanthosis nigricans and skin tags, apple-shaped adiposity
• Likely diagnoses: Class II obesity; PCOS by Rotterdam criteria (hyperandrogenism and ovulatory dysfunction); insulin resistance with prediabetes and hyperinsulinemia; dyslipidemia; restrictive eating patterns; binge eating disorder; weight cycling; probable non-alcoholic fatty liver involvement

How I Think About Eloise’s Physiology

From the start, I appreciate that Eloise is highly active, yet metabolically resistant. This dichotomy suggests entrenched insulin signaling impairments and androgenic influence. Several physiological themes stand out:

• Insulin resistance and hyperinsulinemia: Her fasting insulin of 36.1 is markedly high. Chronically elevated insulin shunts substrate into storage, inhibits lipolysis, and drives hepatic de novo lipogenesis. It also interacts with ovarian theca cells, increasing androgen synthesis, which worsens acne, hirsutism, and anovulation.
• PCOS and reproductive dysfunction: PCOS is fundamentally a neuroendocrine-metabolic disorder with hyperandrogenism, abnormal LH: FSH dynamics, impaired folliculogenesis, and chronic anovulation. Insulin’s permissive effect on ovarian androgen production and hepatic SHBG suppression amplifies free androgen fractions, aggravating hair growth and acne. The cumulative effect is irregular cycles and infertility.
• Dyslipidemia and hepatic stress: Elevated triglycerides and low HDL often accompany insulin resistance. Hepatic insulin resistance plus high insulin promotes steatosis and transaminase elevations, increasing cardiometabolic risk.
• Appetite regulation and binge episodes: Her anxiety around exceeding 1200 calories is a red flag for restrictive eating patterns. The physiologic response to chronic restriction includes increased ghrelin, decreased leptin signaling sensitivity, and heightened reward-driven eating, making evening cravings and binge episodes more likely—especially under stress or after perceived “diet failure.”
• Body composition risks from weight cycling: Repeated cycles of aggressive calorie restriction and regain can reduce lean mass over time while increasing fat mass, exacerbating insulin resistance and lowering resting energy expenditure.

Our Integrative Care Pathway for Eloise

Medical Direction and Safety

Under Dr. Maria Cardenas’s oversight, we confirmed the metabolic profile, identified PCOS by Rotterdam criteria, and outlined a pharmacotherapy plan, contraception strategy, and lab monitoring cadence. Her internal medicine expertise ensures appropriate dosing, contraindication screening, and interdisciplinary communication.

Chiropractic Integration

My chiropractic care targets spinal and pelvic alignment, thoracic mobility, and lower extremity biomechanics to maintain pain-free movement and optimize training consistency. Improved proprioception and neuromuscular coordination enhance autonomic balance, reducing sympathetic overdrive that often accompanies metabolic stress and anxiety. Adjustments and soft-tissue work facilitate efficient gait patterns for the added daily walks and prevent overuse injuries in her high-activity schedule.

Functional Medicine Analytics

We examined gut function, micronutrient status, inflammation markers, sleep quality, and stress loads. Given her restrictive intake history, we focused on adequate protein, omega-3s, magnesium, vitamin D, and potential iron and B-vitamin assessments, which can affect energy levels, hair follicles, and metabolic enzymes.

Nutrition Strategy: Reduced Carbohydrate, Patterned Eating

Why reduced carbohydrate?

With significant insulin resistance, moderating carbohydrates flattens postprandial insulin spikes, supports hepatic fat reduction, and restores insulin sensitivity. In PCOS, this modulates ovarian steroidogenesis and can improve cycle regularity and ovulation probability.

Meal frequency and structure

I guided Eloise to 4–5 small meals/day, eating every 3–4 hours. This counters the feast-famine signal and reduces evening hyperphagia. Regular timing stabilizes glycemia and lowers perceived scarcity, reducing binge triggers tied to the 1200-calorie ceiling.

Protein targets

We aimed for 90–100 grams/day. Sufficient protein supports lean mass retention during weight loss, increases satiety, and can moderate ghrelin fluctuations. Preserving muscle improves insulin-mediated glucose disposal and resting metabolic rate.

Fiber emphasis

We set 50–100 grams/day from vegetables, fruits, and low-glycemic sources. Fiber slows carbohydrate absorption, feeds gut microbiota that produce short-chain fatty acids (SCFAs), and improves satiety signals. SCFAs like butyrate influence GLP-1 secretion and intestinal barrier integrity, reducing endotoxemia and low-grade inflammation that worsens insulin resistance.

Minimize ultra-processed foods

Ultra-processed foods often combine refined starches, sugars, and fats that trigger reward-driven intake and glycemic volatility. Removing these inputs stabilizes cravings and helps dismantle the binge cycle.

Physical Activity Optimization

Eloise already excels in structured exercise. We added daily 10-minute walks, a potent, practical insulin-sensitizing tool. Short, frequent post-meal bouts help clear glucose and reduce peak insulin requirements. I ensured her biomechanics and foot/ankle alignment supported comfortable walks without compensatory strain.

Pharmacologic Plan Under Internal Medicine Oversight

Metformin

We initiated extended-release 500 mg daily, titrating toward 2000 mg as tolerated. Mechanistically, metformin improves hepatic insulin sensitivity, reduces gluconeogenesis, and may positively affect ovarian function in PCOS. It can decrease androgen levels and improve menstrual regularity. Extended-release mitigates GI side effects.

Contraception strategy

Combined oral contraceptives are recommended in PCOS to suppress LH-driven androgen production and raise SHBG, lowering free testosterone. We started contraception immediately because a 5–10% weight loss may restore ovulation, raising pregnancy risk. Under Dr. Cardenas’s guidance, we also planned for pregnancy safety considerations around medications.

GLP-1/GIP therapy: Tirzepatide

After metformin tolerance, we introduced tirzepatide, titrating up to a clinically effective dose (10–15 mg range as needed). Tirzepatide enhances glucose-dependent insulin secretion, reduces glucagon, slows gastric emptying, and strongly reduces appetite. Its dual incretin action promotes substantial weight loss and cardiometabolic improvement. For oral contraceptive users, delayed gastric emptying may reduce pill absorption during the first 4 weeks and after each dose increase; we advised barrier methods during those windows or a non-oral contraceptive alternative, aligning with safety best practices.

BED Management

GLP-1 therapy often dampens binge drivers by improving satiety and reducing reward salience. If residual BED persists, lisdexamfetamine—a medication FDA-approved for BED—can be considered in collaboration with behavioral therapies. We monitor blood pressure, sleep, and anxiety during its use.

Behavioral Supports

We reframed success away from rigid calorie ceilings and toward stable patterns, protein and fiber targets, stress management, and sleep protection. We normalized setbacks, highlighting learning and recovery rather than shame or over-restriction, dismantling the restrict-binge loop.

Six-Month Outcomes: Tangible Metabolic Gains

• Weight: 11% reduction
• Fasting insulin: Decreased from 36.1 to 21.4
• Fasting glucose: Improved
• HOMA-IR: Down substantially
• A1C: Reduced toward normal range
• Dyslipidemia: Improved
• Liver enzymes: Improved
• Binge eating: From 1–2 times/week to 1–2 times/month, commonly stress-triggered
• Physical activity: Maintained high-volume training with added walks
• Sleep and alcohol: Sleep stable; alcohol reduced to minimal levels

Clinical Interpretation

These improvements reflect restored insulin sensitivity, decreased androgenic drive, improved hepatic function, and stabilized appetite regulation. The reduction in binge episodes, especially the decoupling from calorie anxiety, indicates successful cognitive and physiologic retraining. Her high activity now works synergistically with improved metabolic signaling.

Transform Your Body!- Video

Two-Year Outcomes: Sustained Metabolic Flexibility and Fertility Readiness

• Weight: 24.1% reduction
• Fasting insulin: 8.4 (near optimal; target 5–6)
• HOMA-IR: Normal
• A1C: 5.2
• Dyslipidemia: Normalized or near-normal
• PCOS signs: Acne and hirsutism reduced; cycles expected to normalize with contraceptive changes and metabolic stabilization
• BED: Controlled with addition of lisdexamfetamine when needed
• Contraception: Transition planning to barrier method to assess cycle regularity before conception
• Physical activity, sleep, alcohol: Stable and optimal

Why These Outcomes Matter

In PCOS and obesity, long-term cardiometabolic risk is significantly elevated—higher rates of type 2 diabetes, NAFLD, hypertension, and atherosclerosis. By reducing insulin resistance, normalizing lipids, and stabilizing weight with preserved lean mass, Eloise has dramatically changed her lifelong risk trajectory. Fertility planning can proceed on a foundation of optimized metabolic health, improving maternal-fetal outcomes. 

Men’s Case Study:  George’s Journey Through Metabolic Syndrome and Infertility

Now, let’s explore how this approach works in practice by examining the case of a patient I’ll call George.

Initial Presentation: Understanding George’s Story

George, a 35-year-old project manager for a tech company, first came to our clinic with a heavy heart and a list of growing concerns. He is a non-smoker, married, and he and his spouse were in the emotionally taxing process of trying for their second child, having already faced significant difficulties conceiving their first. This struggle was compounded by recent medical news: he had been told his sperm count was low.

During our initial consultation, George painted a picture of a life under immense pressure. He was experiencing symptoms he identified as depression and anxiety, which were fueled by stress from both his demanding job and his personal life. His blood pressure had been consistently elevated, a fact that worried him deeply.

To truly understand a patient, we must look beyond the lab values and symptoms and into the narrative of their daily life. This is a core tenet of functional medicine. George’s story revealed several key factors:

• Work-Related Stress: He was striving for a promotion, which involved long hours and high expectations.
• Environmental Factors: His daily commute was long and stressful. His workplace, like many in the tech industry, provided an abundance of free food and drinks, creating an environment of constant temptation.
• Personal Stressors: Beyond the challenges of conception, he and his spouse were attempting to buy a new home in a better school district, adding a significant financial and logistical burden.
• Psychological Impact: The diagnosis of low sperm count was, in his words, “pretty distressing.” A painful family history magnified his anxiety about his high blood pressure—his father had been diagnosed with heart failure, a condition George correctly understood was linked to untreated hypertension.
• Intimate Health Concerns: He also confided that he experienced occasional erectile dysfunction, which he was attributing to the overwhelming stress in his life.

This holistic intake process is crucial. It’s not just about collecting data; it’s about building a therapeutic alliance and understanding the web of interconnected factors that constitute a person’s health status. George’s case was clearly not just about a single diagnosis but about a systemic imbalance driven by lifestyle, environment, and psychology.

The Objective Data Connecting the Dots

About three months before seeing me, George had a complete physical with another provider. The data from that visit, combined with our own in-clinic measurements, began to illuminate the physiological reality behind his symptoms.

Here’s what the objective findings revealed:

• Concerning Weight Trends: He had been gaining weight, and he expressed shame and a lack of control over his hunger.
• Poor Sleep: He reported not sleeping well, a critical piece of the puzzle that often exacerbates hormonal and metabolic issues.
• Vital Signs:

• Waist Circumference: His waist measurement was elevated. For men, a waist circumference greater than 40 inches (102 cm) is a key indicator of central obesity and a major risk factor for metabolic syndrome.
• Blood Pressure: His readings were consistently in the elevated range, confirming his concern and placing him at increased risk for cardiovascular events.

• Laboratory Findings:

• Fasting Glucose and Insulin: Both were significantly increased.
• HOMA-IR (Homeostasis Model Assessment for Insulin Resistance): This is a calculation we use to quantify insulin resistance. It’s derived from fasting glucose and fasting insulin levels. George’s HOMA-IR score was 1. A score above 1.9 indicates early insulin resistance, and a score above 2.9 is a strong indicator of significant insulin resistance. George was well into the insulin-resistant category.
• Lipid Panel: His cholesterol panel showed some elevations, consistent with developing dyslipidemia.
• Normal Findings: His kidney function and electrolytes were within normal limits.

However, there were conspicuous gaps in his previous lab work. Critical markers like Hemoglobin A1c (A1c), a full thyroid panel, and a liver panel were missing. These are non-negotiable for a comprehensive metabolic workup. An A1c would give us a three-month average of his blood sugar control, a thyroid panel is essential because thyroid dysfunction can mimic and exacerbate metabolic and mood disorders, and a liver panel is crucial, especially given the link between insulin resistance and Non-Alcoholic Fatty Liver Disease (NAFLD).

The Chemical vs Character Conversation De-Stigmatizing Obesity

One of the most profound and damaging aspects of chronic weight gain is the immense shame and guilt patients often feel. George explicitly told us he was “ashamed he doesn’t have better control of that hunger.” This is a critical moment in the patient-provider relationship. It is an opportunity to reframe the entire conversation from a failure of willpower to a matter of biochemistry.

I call this the “Chemical versus Character” discussion. I explained to George that what he was experiencing was not a personal failing or a lack of character. Instead, his body was in the grip of powerful, chemically driven feedback loops that were overriding his best intentions. Understanding this is the first step toward releasing the self-blame and internal bias that so often sabotage a patient’s progress.

This conversation is more than just a pep talk; it’s a crucial piece of patient education grounded in endocrinology. We walk through the science, explaining how obesity and hormone changes engage in a positive feedback cycle—not “positive” as in good, but “positive” as in self-amplifying. The obesity drives the hormone changes, and the hormone changes, in turn, drive the obesity.

The Vicious Cycle of Hormonal Imbalance in Obesity

To help George—and readers of this post—understand this complex interplay, I break it down visually and conceptually. Imagine a complex web where pulling on one thread causes the entire structure to tighten.

1. Excess Adipose Tissue and Sex Hormones:

• • Aromatase Activity: Adipose tissue (body fat) is not just an inert storage depot; it is a highly active endocrine organ. It contains an enzyme called aromatase.
  • Testosterone to Estrogen Conversion: Aromatase converts androgens, like testosterone, into estrogens. In men with excess adipose tissue, particularly visceral fat (the fat around the organs), this aromatase activity is significantly increased.
  • The Result: This leads to a decrease in circulating free testosterone and a simultaneous increase in estrogen levels. This hormonal shift has profound consequences:

• It can contribute to symptoms like fatigue, low libido, erectile dysfunction, and depression.
• It further promotes fat storage, particularly in the visceral region, thus amplifying the cycle.
• Critically for George, optimal testosterone levels are essential for spermatogenesis (sperm production). Low testosterone is a well-established cause of low sperm count and male infertility (Ramasamy et al., 2014).

• Cortisol, Insulin, and Appetite:

• The Stress Connection: George’s high-stress life and poor sleep were keeping his cortisol levels chronically elevated. Normally, cortisol follows a diurnal rhythm, peaking in the morning to help us wake up and declining throughout the day. Chronic stress disrupts this rhythm, leading to sustained high levels.
• Cortisol’s Role: High cortisol directly stimulates appetite, particularly for high-fat, high-sugar “comfort foods.” It also promotes insulin resistance.
• Insulin Resistance: When cells become resistant to insulin, the pancreas has to produce more and more insulin to manage blood sugar. High insulin levels (hyperinsulinemia) are a powerful signal for the body to store energy as fat, especially as visceral fat. This visceral fat is particularly inflammatory and metabolically disruptive.

• The Hunger and Satiety Hormones: Ghrelin, Leptin, and GLP-1:

• Ghrelin: This is often called the “hunger hormone.” It is produced in the stomach and signals the brain that it’s time to eat. In the state of insulin resistance and hormonal imbalance George was experiencing, ghrelin levels tend to be dysregulated, often rising and promoting persistent hunger.
• Leptin: This is the “satiety hormone,” produced by fat cells. It signals the brain that the body has enough energy stores and that appetite can be suppressed. However, in obesity, a state of leptin resistance occurs. The brain becomes deaf to the high levels of leptin, so even with ample fat stores, the “stop eating” signal is never received.
• GLP-1 (Glucagon-Like Peptide-1): This is an incretin hormone produced in the gut in response to food intake. It has multiple beneficial effects: it enhances insulin secretion, suppresses glucagon (a hormone that raises blood sugar), slows gastric emptying (making you feel full longer), and acts directly on the brain to increase satiety. In states of metabolic dysfunction, GLP-1 signaling is often impaired.
• The Net Effect: The combination of high ghrelin, leptin resistance, and poor GLP-1 function creates a perfect storm: a ravenous, uncontrollable appetite and a profound lack of satiety. This is the “chemical” reality that makes George feel he has no control.

• Inflammation and the Final Turn of the Screw:

• Visceral adipose tissue releases a host of inflammatory molecules called adipokines (e.g., TNF-alpha, IL-6). This chronic, low-grade inflammation further worsens insulin resistance and contributes to the long-term risk of cardiovascular disease, diabetes, and even some cancers.
• This entire cascade—the hormonal shifts, the appetite dysregulation, the inflammation—feeds back on the brain. The inability to control cravings leads to more self-blame, negative internal dialogue, and feelings of failure. This psychological distress further increases the stress hormone cortisol, tightening the loop and making the entire situation worse.

By explaining this process, we empower the patient. George began to see his struggle not as a moral failing but as a physiological condition that could be addressed with a targeted, scientific approach.

Defining Patient-Centered Goals

After laying this groundwork, the most important question follows: “George, given all of this, what are your health goals? What matters most to you?” It’s tempting for clinicians to focus on numbers—the weight, the A1c, the blood pressure. But lasting change is driven by the patient’s intrinsic motivation.

George’s goals were clear and compelling, and notably, weight loss itself was not his primary stated goal. Instead, it was a means to an end. He wanted to:

• Improve his heart health and prevent diabetes, driven by the fear of repeating his father’s history.
• Improve his fertility so he and his spouse could conceive their second child.
• Effectively manage his stress.
• Have the energy to be an active, playful father to his child and future children.

These are powerful, emotionally resonant goals. Our treatment plan would be designed to achieve these outcomes, with the understanding that improvements in weight and metabolic markers would be the physiological mechanisms to get him there.

The Initial Treatment Plan: A Multi-Pronged Strategy

Our initial steps for George were comprehensive, addressing the key issues we had identified. This is where our collaborative model with Dr. Cardenas is so vital.

1. Complete the Diagnostic Picture: We immediately ordered the missing labs:

• Hemoglobin A1c: To get a clear picture of his average blood sugar over the past three months.
• Comprehensive Thyroid Panel: Including TSH, Free T4, Free T3, and thyroid antibodies to rule out any thyroid-mediated component.
• Liver Panel (Hepatic Function Panel): To assess for any liver stress or damage, such as NAFLD.

• Medical Management (Overseen by Dr. Cardenas):

• Start Blood Pressure Medication: With his consistently high readings, immediate intervention was necessary to protect his cardiovascular system. Dr. Cardenas prescribed an appropriate antihypertensive medication.
• Home Blood Pressure Monitoring: We instructed him to purchase a home blood pressure cuff and keep a log. This empowers the patient, provides valuable data between visits, and helps us titrate medication effectively.

• Referrals to Allied Health Professionals:

• Registered Dietitian Nutritionist (RDN): Lasting dietary change requires expert guidance. An RDN could provide George with practical, personalized strategies for navigating his work environment and making healthier choices at home.
• Sleep Medicine Specialist: His poor sleep was a major driver of his hormonal chaos. A formal sleep study was necessary to rule out or diagnose conditions like obstructive sleep apnea (OSA), which is extremely common in individuals with obesity and insulin resistance.

• Discussion of Obesity Pharmacotherapy: We introduced the concept that medications could be a powerful tool to help reset the “chemical” imbalances we had discussed. This wasn’t about a “magic pill” but about using evidence-based medicine to help him regain control over his appetite and metabolism, creating a window of opportunity for lifestyle changes to take root.
• Lifestyle Interventions:

• Meditation: To address his high stress and cortisol levels, we discussed simple, accessible meditation techniques.
• Physical Activity Goals: We started the conversation about incorporating more movement into his day.

This initial plan was ambitious but necessary. We were laying the foundation for a long-term transformation.

The Four-Week Follow-Up: Progress, Setbacks, and Reframing the Narrative

Four weeks later, George returned to the clinic. Follow-up visits are where the real work of chronic disease management happens. They are about assessing progress, troubleshooting barriers, and providing continuous support and education.

The Wins: Celebrating Every Step Forward

It’s crucial to start by highlighting what went right. This reinforces positive behaviors and builds momentum. George had several significant achievements:

• He had started the blood pressure medication as prescribed by Dr. Cardenas and, importantly, had diligently kept a blood pressure log, which he brought to the visit. This level of engagement is a fantastic sign.
• He had completed his lab work. We could now see the full picture. His thyroid and liver panels were normal, which was great news. However, his A1c was 5.9%. This officially placed him in the prediabetes range (5.7% to 6.4%), confirming our suspicions and underscoring the urgency of our interventions.
• He had scheduled his sleep study for the following week.
• He had already had his first visit with the dietitian. This proactive step showed his commitment. He also mentioned that the dietitian had reinforced our conversation about obesity medications, making him more open to the idea.

The Challenges Normalizing the Journey

However, the journey wasn’t linear. George had also faced setbacks:

• He hadn’t been able to start the meditation or physical activity.
• His weight had increased slightly.

This is a critical juncture. It would be easy to label this as “non-compliance.” But that is a stigmatizing and counterproductive term. I asked George a simple, non-judgmental question: “Does this surprise you?”

His response was honest. He shared what he had discovered through his work with the dietitian:

• He was eating larger portions than he had realized.
• He was struggling to switch from soda to water.
• He identified that he was stress eating both at work and at home.

This is not failure; it is data. It provides insight into his patterns and triggers. We must reassure patients that fluctuations are a normal part of the process. I often tell my patients that health is a marathon, not a sprint. There will be ups and downs. The scale is a dynamic measure, reflecting fluid shifts, food intake, and more—it does not always reflect fat loss or gain, nor does it reflect their effort. Our role is to normalize this experience, analyze the contributing factors without judgment, and collaboratively chart a path forward.

Addressing the Barriers

We then dug deeper into the barriers. Why had the meditation and exercise not happened?

• Meditation: George admitted he “felt a little bit silly” doing it. This is a common feeling. The barrier wasn’t time; it was self-consciousness.
• Physical Activity: He reported he “hasn’t had the energy.” This is a key insight. We can’t just tell an exhausted, insulin-resistant patient to “exercise more.” We have to address the underlying fatigue first.

With these barriers identified, we could adjust the plan to be more realistic and targeted.

Adjusting the Plan: A More Targeted Approach

Based on the follow-up, we refined our strategy:

1. Medication Adjustments (with Dr. Cardenas):

• • Blood Pressure: His blood pressure, while better, was not yet at our target. Dr. Cardenas decided to increase the dose of his antihypertensive medication.
  • Obesity and Mood Medication: We discussed starting a combination medication: bupropion-naltrexone. This was a strategic choice for several reasons:

• Bupropion: An antidepressant that can also help with low energy and focus due to its mildly stimulating effects. It would directly address George’s reported depression and anxiety.
• Naltrexone: An opioid antagonist that works on the brain’s reward pathways. It is particularly effective at reducing cravings for food, especially sugar. This would directly target the soda cravings and stress eating he was struggling with.

• • Timing: Because bupropion is stimulating, we instructed George to wait until after his sleep study to start this medication, as it could interfere with the results.
• Overcoming Lifestyle Barriers:

• “Silly” Meditation Solution: To overcome his self-consciousness, we proposed a new plan. He would download a meditation app and try a simple three-minute guided meditation in his car after his stressful commute, before walking into the office. This provided privacy and a structured, low-commitment starting point. The goal was just twice a week to start. Small, achievable goals are key.
• “No Energy” Exercise Solution: Instead of structured “exercise,” we reframed it as “moving more.” We asked him to get up from his desk more often, take the stairs instead of the elevator, and use his phone or a watch to remind him. Small bursts of activity throughout the day can be just as, if not more, effective than a single, daunting workout session, especially in the beginning.

• Continued Support: We encouraged him to continue his great work with the dietitian and, of course, to complete the upcoming sleep study.

The Four-Month Follow-Up: Turning the Corner

Four months later, George returned, and the transformation was palpable. The targeted adjustments had paid off, and he was beginning to feel the positive effects of his hard work.

The Tangible Improvements:

• Blood Pressure: Now well-controlled on the adjusted medication dose.
• Sleep: His sleep study had confirmed obstructive sleep apnea (OSA), and he was now using a CPAP (Continuous Positive Airway Pressure) machine at night. This was a game-changer. Treating OSA is one of the most powerful interventions for improving insulin sensitivity, lowering blood pressure, reducing cortisol, and increasing daytime energy.
• Mood: His mood had noticeably improved. He was still meditating and finding it genuinely helpful for stress management.
• Activity: He was now consistently going for walks during his lunch breaks. A new watch that reminded him to stand and move had been a helpful tool.
• Weight and Nutrition: His weight was down, and his nutritional habits had significantly improved, with his dietitian reporting great progress.

A New Challenge: The Appetite Persists

Despite all this wonderful progress, George reported one lingering issue: “I’m still very hungry. My appetite’s just not well controlled.” He also mentioned that a friend had told him about an injectable medication for weight loss and was curious.

This is a perfect example of the “Chemical vs. Character” issue. Even with improved sleep, mood, and diet, his underlying hormonal dysregulation of appetite (the ghrelin, leptin, and GLP-1 pathways) was still a powerful force. His body’s set point for weight was fighting back.

His question about injectable medication showed that he was now an engaged and educated partner in his own care. He was ready for the next level of intervention.

The Next Evolution of Treatment: Incretin Mimetics and Body Composition

His upcoming goal of trying to conceive again in a few months added a layer of consideration to our next steps.

1. Introducing Incretin-Based Therapy:

• We had a refreshed conversation about the risks and benefits of the injectable medications he mentioned, which are known as GLP-1 receptor agonists (e.g., semaglutide, liraglutide).
• These medications work by mimicking the action of the natural hormone GLP-1. They directly target the “chemical” problem: they increase satiety, slow stomach emptying, and help regulate blood sugar. For someone like George, whose primary remaining barrier was appetite, this was an ideal therapeutic target.
• We checked his insurance, and fortunately, he had coverage. Dr. Cardenas prescribed semaglutide, starting at the initial dose of 0.25 mg weekly.

• Streamlining Medications:

• With the start of semaglutide to powerfully address appetite, the naltrexone component of his previous medication was less critical.
• To continue supporting his mood while simplifying his regimen, we decided to taper him off the bupropion-naltrexone combination and have him continue with bupropion alone.

• Shifting Focus to Body Composition:

• As patients lose weight, especially with powerful medications like GLP-1 agonists, it is absolutely critical to ensure they are losing fat mass, not precious muscle mass.
• The Role of Chiropractic and Rehab: This is an area where my chiropractic and rehabilitation background is particularly valuable. We must integrate resistance training into the plan.
• We instructed George to schedule a body composition analysis (like a DEXA or InBody scan). If that wasn’t accessible, even a home scale with bioimpedance technology could provide useful trends. The absolute numbers are less important than the trend over time. We needed to see his body fat percentage decrease while his muscle mass was maintained or, ideally, increased.
• We gave him a new goal: to add weight resistance training to his routine in addition to his walking. This could be bodyweight exercises, resistance bands, or free weights. Preserving muscle is paramount for maintaining a healthy metabolic rate long-term.

One Year Later Achieving the Ultimate Goals

George’s one-year follow-up visit was a celebration. The comprehensive, iterative, and patient-centered plan had yielded incredible results, not just on paper, but in the areas of his life that mattered most to him.

The Fantastic News:

• The best news of all: His spouse was pregnant and due with a baby girl in three months. Our focus on improving his metabolic health, reducing inflammation, and balancing his hormones had directly and successfully impacted his fertility.
• His blood pressure remained consistently controlled.
• He was continuing on bupropion for his mood and semaglutide for appetite and metabolic control. Importantly, he had found that a dose of 7 mg of semaglutide was perfect for him. He did not need to titrate all the way to the maximum dose of 2.4 mg. This is a key point: the goal is to find the lowest effective dose for maintenance, which can vary greatly between individuals. Some patients may even be able to titrate back down for long-term weight maintenance.
• He was still getting his walks in, though he was no longer formally meditating, having integrated other stress-management techniques into his life.

The Objective Transformation: A Side-by-Side Comparison

Let’s look at the numbers, which tell a stunning story of physiological recovery:

Marker	Initial Visit	One-Year Follow-Up	Status
Weight	Elevated	Significantly Down	Improved
Waist Circumference	Elevated (>40 in)	Significantly Down	Improved
Blood Pressure	Elevated	Controlled	Resolved
Fasting Glucose	Increased	Normal	Resolved
Fasting Insulin	Increased	Normal	Resolved
HOMA-IR Score	3.1 (Insulin Resistant)	1.64	Resolved
Hemoglobin A1c	5.9% (Prediabetic)	Normal	Resolved

His HOMA-IR score of 1.64 was now well within the optimal range (we aim for less than 1.9), indicating his insulin sensitivity had been restored. He was no longer prediabetic.

Conclusion: A New Beginning

At his one-year visit, George was a different man. He felt healthy again. He was checking in with the dietitian less frequently and felt empowered to manage his own nutrition. Most importantly, he had achieved the goals he set out for himself:

• He had improved his heart health.
• He had prevented the progression to type 2 diabetes.
• He had improved his fertility.
• He had learned to manage his stress.
• He had the energy he craved to be an active father.

He was now ready to set new goals for long-term health maintenance, confident in his ability to stay on track. George’s journey is a powerful testament to the principles of integrative and functional medicine.

Case Integration: Amin’s Journey Through Insulin Resistance and Body Composition Change

I will recount Amin’s story from my perspective as we evaluated his metrics and shaped the plan with Dr. Cardenas.

Amin’s Baseline and Early Progress

When Amin first came to us, he was on exogenous insulin. That limited the interpretability of his endogenous insulin profile. As we advanced his care—optimizing nutrition, activity, and gradually tapering exogenous support under Dr. Cardenas’s supervision—we reached a point where we could test his endogenous insulin and its interplay with fasting glucose and A1C.

• Fasting insulin: 22.4 μIU/mL (elevated)
• A1C: 6.3 percent (improved from his prior values)
• HOMA-IR: 5.8 (still elevated, indicating insulin resistance)
• Liver enzymes: improving
• Body fat: reduced from 56.7 percent to 48.9 percent
• Skeletal muscle mass: slightly rising despite weight loss
• Visceral adipose tissue: decreased from 4.4 L to 3.5 L
• Waist circumference: down
• Activity adherence: 15 minutes per day cycling, to extend toward 30 minutes
• Strength training: twice weekly, gradually increasing resistance
• Nutrition adherence: approximately 75 percent, aiming for 85 percent
• Pharmacotherapy: semaglutide 2.4 mg with an eye toward adjunctive options if hunger or cravings reemerged

Physiological significance:

• Elevated fasting insulin and HOMA-IR reflect compensatory hyperinsulinemia and insulin resistance. The combination is associated with hepatic steatosis, increased VLDL production, endothelial dysfunction, and pro-inflammatory adipokine signaling.
• Falling A1C and improving liver enzymes suggest that hepatic insulin sensitivity and glucotoxic stress are easing.
• Reductions in visceral adipose tissue are particularly meaningful; VAT is metabolically active and associated with portal free fatty acid flux, hepatic insulin resistance, IL-6, TNF-alpha signaling, and atherogenic dyslipidemia.
• The small but real increase in skeletal muscle mass during weight loss is an important protective factor. Muscle is the primary reservoir for postprandial glucose disposal via GLUT4-mediated uptake and is critical for basal metabolic rate.

The Plan for Amin: Stepwise, Integrated, Compassionate

I often emphasize micro-progression: the art of gently increasing capacity without triggering pain flares or burnout. For Amin, who was cycling 15 minutes daily, we asked a simple question: Could we do 16 or 17 minutes? A week later, 18 or 19? This incremental approach respects the neurobiology of habit formation and the musculoskeletal limits of a deconditioned system.

Our integrated plan included:

• Nutrition

• Move adherence from 75 percent to at least 85 percent.
• Maintain high-protein, whole-food emphasis to protect muscle.
• Manage carbohydrate timing and fiber intake for glycemic control and satiety.

• Activity

• Cycling: increase from 15 to 30 minutes as tolerated.
• Strength training: maintain twice weekly, progressive overload approach, watching for form and joint tolerance.
• NEAT (non-exercise activity thermogenesis): park farther, take short walks, accumulate step volume.

• Chiropractic integration

• Thoracolumbar mobility to reduce paraspinal guarding and allow better cycling posture.
• Pelvic and hip adjustments to offload knee tracking and enhance stroke efficiency on the bike.
• Soft tissue mobilization for hip flexors, glutes, and TFL to improve pedal mechanics and minimize overuse.

• Pharmacotherapy and medical oversight
  • Continue semaglutide 2.4 mg as long as hunger and portion control remain favorable.
  • If hunger resurges—due to metabolic adaptation and homeostatic defense of body fat—we would consider adjunctive agents such as phentermine, bupropion, or topiramate, understanding:

• Phentermine targets sympathetic activation to reduce appetite.
• Bupropion modulates dopaminergic/noradrenergic pathways, reducing hedonic eating.
• Topiramate may reduce impulsivity and caloric intake.

• • We would not combine GLP-1 receptor agonists.

Why hunger can return despite progress

Weight reduction triggers multiple adaptive responses:

• Increased ghrelin (hunger hormone)
• Reduced leptin (fat-derived satiety signal)
• Reduced peptide YY and cholecystokinin
• Hypothalamic defense of set-point via altered neuronal signaling
• Reduced energy expenditure disproportionate to lost weight (adaptive thermogenesis)

These physiologic countermeasures are normal, not failures. Our job is to normalize this for Amin and ensure he feels supported rather than blamed.

One-Year Outcome for Amin

At the one-year mark:

• Weight reduction: 16.3 percent
• Fasting insulin: down to 13.1 μIU/mL (substantially lower)
• HOMA-IR: improved to 3.4 (still elevated but trending right)
• A1C: 6.0 percent
• Body fat: from 56.7 percent to 41.1 percent
• Skeletal muscle mass: up to 29.1 percent (25th percentile)
• Visceral adipose tissue: 4.3 L (note: initial reported drop to 3.5 L earlier—VAT may fluctuate with hydration, measurement variance, or serial methodology; overall trend remains favorable)
• Claudication pain: minimal
• Activity: 30 minutes cycling most days, strength training twice weekly

Clinical interpretation:

• A remarkable reduction in cardiometabolic risk, improved exercise capacity, and functional vitality.
• Preservation and modest improvement of muscle mass against the headwind of weight loss—a clinically meaningful achievement.
• Reduced claudication suggests improved endothelial function, peripheral blood flow, and muscular efficiency, aided by lower systemic inflammation and consistent, graded activity.

Chiropractic’s role at one year:

By maintaining spinal mobility, hip alignment, and ankle dorsiflexion capacity, Amin tolerated progressive cycling intensity and duration without overloading his lumbar segments or patellofemoral joint. Neuromechanical optimization catalyzed adherence by making movement more comfortable and enjoyable.

Dolores’s Story: Navigating Osteoarthritis, Sarcopenia, and Healthcare Bias

Dolores, age 72, is a retired wealth advisor with two adult children. She is ready to travel and wants both knees replaced due to severe osteoarthritis (OA). Her immediate objective is to reduce weight to qualify for surgery, given a BMI threshold of less than 40 at her hospital.

Baseline Snapshot

• Medical History: Hyperlipidemia, insomnia (improved with trazodone), severe bilateral knee OA
• Medications: rosuvastatin, trazodone, diclofenac, multivitamin
• Physical activity: swimming 20 minutes, three days per week; walking limited by knee pain
• Nutrition: three meals per day; low protein overall; high fruit/vegetable intake; sweets in evening
• Sleep: chronic insomnia improved on trazodone; occasional early awakenings
• Metabolic labs: relatively healthy profile overall
• Fasting insulin: 8.4 μIU/mL (slightly elevated)
• BMI: 41.5
• Body fat: 56.8 percent
• Skeletal muscle mass: 15.1 percent (second percentile—significant sarcopenia)
• Visceral fat: 2.3 L
• Waist circumference: 43.1 inches
• Fat distribution: predominantly central adiposity over gynoid baseline (perimenopause-triggered central fat gain)

Clinical concerns:

• Sarcopenia and progressive mobility limitations
• Risk of worsening cardiometabolic health as muscle mass falls further
• Healthcare inequities and weight bias
• Functional limitations preventing adequate activity to achieve necessary weight loss for surgery

Treatment objectives:

• Reduce weight by about 3.9 percent (~10 lbs) to reach surgical criteria
• Improve mobility and strength
• Elevate protein intake to support lean mass accrual
• Implement joint-friendly conditioning and rehabilitation
• Consider pharmacotherapy to facilitate weight loss amid activity constraints

Nutrition Plan

• Protein target: 90–100 grams/day, spaced every 3–4 hours to maximize muscle protein synthesis, particularly crucial for older adults with anabolic resistance.
• Because she dislikes meat:

• Focus on eggs, seafood, cottage cheese, Greek yogurt, cheese, and high-quality protein smoothies/drinks.
• Consider collagen peptide supplementation with leucine-rich protein to support connective tissue along with muscle protein synthesis.

• Evening sweets strategy:

• Protein-forward evening snack with fiber (e.g., Greek yogurt with chia and berries) to stabilize glycemia and reduce hedonic drive.
• Behavioral substitutions and stimulus control for evening craving windows.

Activity and Rehabilitation

• Continue swimming 20 minutes 3x/week—buoyancy reduces joint load while maintaining cardiovascular fitness.
• Add stationary bike per PT recommendation—cycling is typically less painful than walking for knee OA and promotes quadriceps strength without high tibiofemoral compression.
• Strength training with PT guidance—focus on gluteal, hamstring, quadriceps, and calf complex; incorporate hip abductor strengthening to improve frontal-plane knee loading mechanics.

Chiropractic Integration for Knee OA

• Pelvic, sacroiliac, and lumbar adjustments to optimize kinetic chain alignment, reducing medial knee compartment stress.
• Ankle and subtalar joint mobilization to improve dorsiflexion, reducing compensatory pronation and torsional forces on the knee.
• Soft tissue work along the iliotibial band, lateral retinaculum, and hip flexors to normalize patellofemoral tracking.
• Thoracic mobility and posture training to improve balance and reduce fall risk while exercising.

Pharmacotherapy Considerations

• For weight loss support: tirzepatide, semaglutide, naltrexone/bupropion, phentermine, or phentermine/topiramate may be appropriate.
• We carefully weigh benefits against risks in the context of age, comorbidities, insomnia history, and perioperative plans.
• If opioids may be needed post-op, naltrexone must be paused because it blocks opioid analgesia.
• Bupropion alone can be continued if clinically indicated and tolerated.
• GLP-1 or dual agonists can be an effective alternative when appetite suppression and metabolic benefits are needed, and surgical timing allows.

Addressing Biases and Fears

• Weight bias and dismissal in healthcare are real and damaging. I validate Dolores’s experiences and commit to advocacy.
• Fear of PT is common among older women with obesity. Patients fear judgment and failure in front of clinicians. We meet this head-on:

• Role-play conversations before PT visits.
• Seek PTs with understanding of obesity and a compassionate, graded approach.
• Coach Dolores to begin the PT visit by sharing her goals, progress, and needs—taking control of the narrative.
• Offer to communicate with PT and orthopedic teams directly when needed.

BMI Thresholds and Hospital Policies

• Some hospitals set blanket BMI cutoffs (<40) to reduce complication rates, though evidence for absolute cutoffs is mixed.
• Risks of infection and complications may be slightly increased with higher BMI, but long-term benefits of joint replacement can outweigh these risks when individualized.
• We advocate for patient-centered evaluation rather than rigid metrics.

One-Year Outcome for Dolores

• Weight loss: 8.7 percent
• Fasting insulin: returned to normal range
• Body fat: down to 49.8 percent
• Skeletal muscle mass: increased to the 10th percentile (meaningful improvement from second percentile baseline)
• Visceral fat: reduced
• Waist circumference: lower
• Pharmacotherapy timeline:

• Initially added naltrexone/bupropion to facilitate weight reduction amid activity constraints.
• Before surgery, paused naltrexone (to allow effective opioid analgesia if needed) and continued bupropion.
• After first knee replacement (six months before the one-year mark), as mobility and goals evolved, transitioned to semaglutide and titrated up to 1.7 mg, aligning with her plan for a second knee replacement and post-op recovery trajectory.

Functional gains and life goals:

• Improved mobility and stamina with fewer pain flares.
• Successful first knee replacement without complications.
• Preparing for second knee replacement.
• Returning to her dream: travel to Europe.

Physiological Deep Dive: Why Each Intervention Works

Integrative Chiropractic Care in Obesity and PCOS Management

• Biomechanics and autonomic balance: Chiropractic adjustments and soft-tissue interventions enhance spinal mobility and proprioception. Improved thoracic and pelvic mechanics support diaphragmatic breathing, vagal tone, and autonomic stability. Lower sympathetic overdrive reduces cortisol burden that contributes to central adiposity and insulin resistance.
• Pain modulation and movement consistency: By addressing cervical, thoracic, lumbar, and pelvic joints, we minimize pain that otherwise suppresses activity and fosters sedentary behaviors. Consistent movement amplifies insulin sensitivity and supports appetite regulation.
• Neuromuscular efficiency: High-quality motor patterns reduce overuse injuries and improve strength training outcomes, supporting lean mass preservation during weight loss.
• Integration with functional medicine: We coordinate musculoskeletal care with gut health, micronutrients, inflammation, and endocrine imbalances, ensuring that movement prescriptions match metabolic capacity.

Insulin and Adipose Biology

Chronic hyperinsulinemia inhibits hormone-sensitive lipase, suppressing lipolysis and increasing adipocyte triglyceride storage. It drives adipocyte hypertrophy, hypoxia, and inflammatory cytokine release (TNF-α, IL-6), worsening insulin resistance. Lowering insulin via diet and medication re-enables lipolysis and improves adipocyte function. In hepatic insulin resistance, insulin’s suppression of gluconeogenesis is impaired, while lipogenesis can remain elevated. This paradox promotes hyperglycemia and hypertriglyceridemia, with increased VLDL production. Improvements reduce triglycerides and often increase HDL, lowering atherogenic risk.

Incretin Physiology: GLP-1 and GIP

GLP-1 and GIP enhance glucose-dependent insulin secretion, reduce glucagon, slow gastric emptying, and act on central appetite centers to reduce energy intake. Tirzepatide’s dual action produces robust weight loss and glycemic benefits, translating to improved HOMA-IR and A1C. Semaglutide, as a GLP-1 RA, also slows gastric emptying, enhances glucose-dependent insulin secretion, reduces glucagon, and increases satiety through central appetite regulation.

PCOS and Androgen Biology

Hyperinsulinemia increases ovarian theca cell androgen production and decreases hepatic SHBG, elevating free testosterone. Weight loss, metformin, and oral contraceptives reduce androgenic drive, improving acne, hirsutism, and ovulation likelihood.

Protein and Fiber in Metabolic Health

Adequate protein preserves lean mass, stabilizes satiety signals, and supports thermogenesis. High fiber supports SCFA production, GLP-1 secretion, mucosal integrity, and reduced systemic inflammation, all of which favor improved insulin sensitivity and appetite control. Anabolic resistance in older adults requires higher protein dosing (often 1.2–1.6 g/kg/day) and attention to leucine thresholds (~2.5 g leucine per meal) to stimulate muscle protein synthesis.

Muscle as a Metabolic Sink

Each kilogram of muscle substantially contributes to resting metabolic rate and postprandial glucose disposal. Myokine signaling (e.g., irisin, IL-6 in its myokine role) can promote browning of adipose tissue and enhance lipid oxidation, countering ectopic fat accumulation. Without sufficient protein and resistance training, weight loss often leads to sarcopenia, worsening insulin resistance per unit of fat mass lost. Strength training stimulates mTOR pathways and increases neuromuscular efficiency, preserving function and metabolic health.

Collaborative Model: Dr. Cardenas’s Internal Medicine Leadership

Our model relies heavily on the expertise of our Medical Director, Dr. Cardenas, whose role includes:

• Pharmacotherapy governance: Dose selection, titration, and safety monitoring for metformin, tirzepatide, semaglutide, lisdexamfetamine, naltrexone/bupropion, and other agents.
• Lab surveillance: Glucose-insulin dynamics, lipid panels, hepatic enzymes, and reproductive hormones where indicated.
• Contraceptive strategy: Balancing PCOS benefits with GLP-1/GIP therapy considerations and pregnancy planning.
• Comorbidity management: Hypertension, NAFLD, thyroid disorders, and autoimmune conditions.
• Specialist coordination: Endocrinology, dermatology, gynecology, and behavioral health.

Behavioral Medicine and Binge Eating Disorder: A Clinical Approach

• Screening and diagnosis: We incorporate validated tools like BEDS-7 to assess frequency, distress, loss of control, and large-amount eating episodes. Scores above 5 warrant further evaluation for BED.
• Therapeutic frame: We emphasize psychological safety, normalize the learning process, and teach skills for stress-driven cravings. Structured meal timing and adequate protein/fiber reduce physiological binge drivers.
• Pharmacologic adjuncts: Lisdexamfetamine for BED is deployed judiciously under medical oversight, alongside sleep hygiene and blood pressure monitoring.
• Recovery mindset: We transform the narrative from perfectionism to consistency, reducing the all-or-nothing cycles that fuel binge episodes.

Sequencing of Care: Why Stepwise Plans Reduce Risk

• Start with safety and contraception when fertility may change quickly with weight loss and improved insulin sensitivity.
• Introduce metformin to dampen hepatic glucose production and reduce insulin levels.
• Layer GLP-1/GIP therapy to amplify satiety and weight loss, while managing contraceptive absorption issues.
• Stabilize behavior and nutrition patterns before pushing aggressive exercise volumes, prioritizing daily short walks as a potent metabolic tool.
• Add BED-specific medication only if needed, paired with behavioral strategies to ensure durable change.
• When planning joint replacement, we anticipate perioperative analgesia needs and adjust medications accordingly (e.g., pause naltrexone pre-op).

Clinical Observations from My Practice

• High-volume activity without metabolic recalibration can frustrate patients. Once insulin signaling improves, the same training produces outsized benefits.
• Patients who move away from rigid daily calorie caps toward protein/fiber targets and regular timing experience fewer binges and better long-term adherence.
• Chiropractic care that enhances movement confidence reduces fear-driven avoidance. This matters because fear avoidance can perpetuate inactivity and stress, elevating cortisol and appetite.
• Internal medicine oversight prevents gaps in care—especially around contraception and medication timing with GLP-1/GIP agents.
• Patients who receive pain relief and movement optimization early are far more likely to adhere to activity prescriptions, translating to superior metabolic outcomes.

Building Longevity From Weight Loss to Metabolic Resilience

The transition from weight loss to maintenance depends on:

• Preserved lean mass and neuromuscular fitness.
• Flexible, relapse-resistant behavioral strategies.
• Continued medical monitoring for insulin, lipids, and liver enzymes.
• Autonomic balance through stress management, sleep, and movement quality.

Our Multidisciplinary Promise

By uniting internal medicine, chiropractic care, functional medicine, and rehabilitation, we build coherent, safe plans that honor the complexity of obesity. We meet patients where they are, reduce physiological barriers, protect against injury and relapse, and create durable change through personalized, evidence-based strategies. The integration of Dr. Cardenas’s expert medical management with our clinic’s functional medicine and chiropractic rehabilitation framework is the key. We address structural potential through movement, neurological stress through lifestyle changes, and biochemical chaos through targeted nutrition, sleep restoration, and advanced pharmacotherapy. This is the future of healthcare—a partnership with the patient to co-create a vibrant, healthy life.

References

• American Association of Clinical Endocrinologists and American College of Endocrinology. (2016). Comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice.
• American College of Obstetricians and Gynecologists. (2018). Polycystic ovary syndrome. Practice Bulletin.
• American Diabetes Association. (2024). Standards of medical care in diabetes. Diabetes Care.
• Apovian, C. M., Aronne, L. J., et al. (2015). Pharmacological management of obesity. Endocrine Reviews.
• Davies, M. J., Aroda, V. R., & Collins, B. S. (2022). Tirzepatide in type 2 diabetes: Rationale and clinical evidence. The Lancet Diabetes & Endocrinology.
• Davies, M. J., Aroda, V. R., et al. (2021). Efficacy of semaglutide in adults with overweight or obesity. The New England Journal of Medicine.
• DeFronzo, R. A., & Tripathy, D. (2009). Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care.
• Garvey, W. T., Mechanick, J. I., et al. (2016). American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice.
• Garvey, W. T., et al. (2016). Anti-obesity medications and the comprehensive treatment of obesity. Endocrine Practice.
• Haff, G. G., & Triplett, N. T. (2015). Essentials of strength training and conditioning. Human Kinetics.
• Hall, K. D., & Kahan, S. (2018). Maintenance of lost weight and long-term management of obesity. Medical Clinics of North America.
• Heymsfield, S. B., & Wadden, T. A. (2017). Mechanisms, pathophysiology, and management of obesity. NEJM.
• Jastreboff, A. M., Aronne, L. J., et al. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine.
• Jensen, M. D., et al. (2013). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation.
• Kolasinski, S. L., Neogi, T., et al. (2020). 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis. Arthritis Care & Research.
• Kushner, R. F., & Kahan, S. (2018). Obesity medicine: Clinical management of obesity. Springer.
• Kushner, R. F., & Kahan, S. (2018). Obesity treatment focuses on chronic disease management. JAMA.
• Legro, R. S., et al. (2013). Diagnosis and treatment of PCOS. Endocrine Society Clinical Practice Guideline.
• MacLean, P. S., Blundell, J. E., et al. (2017). Biological control of appetite: Implications for weight regain. Obesity Reviews.
• Mechanick, J. I., et al. (2020). Integrative care models for obesity and metabolic syndrome. Journal of the Endocrine Society.
• Messier, S. P., Loeser, R. F., et al. (2018). Exercise and diet in osteoarthritis management. Arthritis & Rheumatology.
• Neeland, I. J., Poirier, P., & Després, J.-P. (2018). Cardiovascular and metabolic heterogeneity of obesity. Circulation.
• Pasiakos, S. M., McLellan, T. M., & Lieberman, H. R. (2015). Higher protein diets and body composition in weight loss. Journal of Nutrition.
• Ramasamy, R., Scovell, J. M., & Kovac, J. R. (2014). Testosterone supplementation and asymptomatic hyperprolactinemia in men with hypogonadism. Translational Andrology and Urology, 3(2), 186–190.
• Rubino, D. M., Greenway, F. L., et al. (2021). Effect of semaglutide on body weight in adults with overweight or obesity. The Lancet.
• Rubino, D., et al. (2021). GLP-1 receptor agonists in obesity: Evidence and mechanism. Nature Reviews Endocrinology.
• Ryan, D. H., & Yockey, S. R. (2017). Weight loss and improvements in comorbidity: Differences at 5, 10, 15 percent. Current Obesity Reports.
• Schiaffino, S., & Reggiani, C. (2011). Fiber types in mammalian skeletal muscles. Physiological Reviews.
• Stanford, F. C., Durso, L. E., et al. (2018). Practical recommendations for addressing weight bias in clinical settings. Obesity.
• Vilsbøll, T., & Holst, J. J. (2004). Incretins in diabetes and obesity. Diabetologia.
• Wadden, T. A., Tronieri, J. S., & Sugimoto, D. (2019). Pharmacotherapy for obesity in patients with type 2 diabetes. Diabetes Spectrum.
• Wilding, J. P. H., Batterham, R. L., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. NEJM.

SEO Tags: integrative chiropractic, obesity treatment, insulin resistance, HOMA-IR, PCOS fertility, Male Infertility, Metabolic Syndrome, Testosterone, visceral adipose tissue, GLP-1 semaglutide, tirzepatide, naltrexone bupropion, phentermine topiramate, metformin PCOS, binge eating disorder care, osteoarthritis knee, sarcopenia, protein intake, cycling therapy, aquatic therapy, functional medicine, internal medicine oversight, El Paso chiropractic clinic, Dr. Maria Guadalupe Cardenas MD, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr Alex Jimenez, body composition, cardiometabolic risk reduction, A1C reduction, weight bias healthcare, perioperative obesity management, Men’s Health, Fertility Treatment, Visceral Fat, Aromatase, Cortisol, Ghrelin, Leptin, High Blood Pressure, Prediabetes, Obstructive Sleep Apnea, Stress Management